ABSTRACT: Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) play complementary roles in follicle development and ovulation via a complex interaction in the hypothalamus, anterior pituitary gland, reproductive organs, and oocytes. Impairment of the production or action of gonadotropins causes relative or absolute LH and FSH deficiency that compromises gametogenesis and gonadal steroid production, thereby reducing fertility. In women, LH and FSH deficiency is a spectrum of conditions with different functional or organic causes that are characterized by low or normal gonadotropin levels and low oestradiol levels. While the causes and effects of reduced LH and FSH production are very well known, the notion of reduced action has received less attention by researchers. Recent evidence shows that molecular characteristics, signalling downstream of gonadotropin receptors, and polymorphisms negatively affect gonadotropin action. These findings have important clinical implications, in particular for medically assisted reproduction in which diminished action determined by the afore-mentioned factors, combined with reduced endogenous gonadotropin production caused by GnRH analogue protocols, may lead to resistance to gonadotropins and, thus, to an unexpected hypo-response to ovarian stimulation. Indeed, the importance of LH and FSH action has been highlighted by the International Committee for Monitoring Assisted Reproduction Technologies (ICMART) in their definition of hypogonadotropic hypogonadism as gonadal failure associated with reduced gametogenesis and gonadal steroid production due to reduced gonadotropin production or action. The aim of this review is to provide an overview of determinants of reduced FSH and LH action that are associated with a reduced response to ovarian stimulation.

Key words: LH / FSH / gonadotropins / LH and FSH deficiency / polymorphisms / recombinant LH / recombinant FSH / hypo-response / ovarian stimulation

Introduction

Folliculogenesis is controlled by a complex interaction among hormones in the hypothalamus, anterior pituitary gland and the ovaries. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are secreted from the anterior pituitary gland in response to GnRH (Conn and Crowley, 1994; Kaiser et al., 1997) and play a complementary role in follicle development and ovulation (Casarini et al., 2018a).

In ovarian theca cells, LH stimulates the secretion of androgens that are transferred to granulosa cells to be converted to oestradiol (E2) by aromatase. In granulosa cells, FSH stimulates the development of ovarian follicles, while LH action is involved in follicle development and maturation. A deficiency in LH and FSH production or action compromises gametogenesis and gonadal steroid production thereby reducing female fertility (Santoro et al., 1986; Huhtaniemi and Themmen, 2005; Wide et al., 2009; Casarini et al., 2018a). Recently, the International
Committee for Monitoring Assisted Reproductive Technologies (ICMART) highlighted the importance of gonadotropin action in determining a deficiency of LH and FSH, and provided a broader definition of hypogonadotropic hypogonadism that encompasses this notion, namely ‘Gonadal failure associated with reduced gametogenesis and reduced gonadal steroid production due to reduced gonadotropin production or action’ (Zegers-Hochschild et al., 2017). While the causes of reduced LH and FSH production are well described (Bianco and Kaiser, 2009), deficiency of LH and FSH action has received much less attention, even though it is now recognized that both production and action are relevant for human fertility and are of clinical interest for medically assisted reproduction (MAR).

The action of LH and FSH is determined by a variety of factors, i.e. the frequency and amplitude of GnRH peaks, the different isoforms of LH and FSH, polymorphisms of FSH and LH and their receptors, and intracellular signalling. Furthermore, in MAR, inter-individual demographic, clinical and treatment factors, such as age, comorbidities, and the effect of oral contraceptives and GnRH analogue protocols, can influence gonadotropin action and the response to exogenous gonadotropins (Anobile et al., 1998; Davison et al., 2005; Alviggi et al., 2009b; Santi et al., 2017). In this review, we focus on the determinants of reduced LH and FSH action that are associated with a reduced quantitative and qualitative response to ovarian stimulation (OS) in the attempt to gain insights that may help to improve the clinical management of women with LH and FSH deficiency undergoing MAR.

**LH and FSH action in physiological and altered conditions**

**The hypothalamic–pituitary–gonadal axis**

LH and FSH production and activity depend on the precise orchestration of numerous elements of the hypothalamic–pituitary–gonadal (HPG) axis (Fig. 1), the functioning of which is regulated by positive and negative feedback loops that occur in parallel with follicular development (Marshall et al., 1991; Berga and Naftolin, 2012). Oestradiol is the hormone most involved in the regulation of the HPG axis, together with progesterone and inhibins. In the early follicular phase, FSH levels increase thereby triggering E2 secretion, which, in turn, selectively inhibits FSH release and maintains rapid GnRH pulsatility during the late follicular phase (Moenter et al., 1992). Negative feedback control of FSH release is also supported by the release of inhibin B from the granulosa cell mass of the follicle. In the late follicular phase, accelerated GnRH pulsatility causes an increase in LH level, which further stimulates E2 secretion. At mid-menstrual cycle, E2 provides a positive feedback to the hypothalamus, thereby causing the LH (and FSH) surge (Pau et al., 1993). After ovulation, luteinization of the ruptured follicle induces progesterone secretion, which has a negative feedback on the hypothalamus, thus reducing the GnRH pulse frequency. Finally, with the demise of the corpus luteum, the levels of E2, progesterone and inhibin A sharply decrease, and the GnRH pulse frequency and FSH secretion increase leading to the next cycle (Marut et al., 1981; Moenter et al., 1992). Moreover, increasing evidence indicates that anti-Müllerian hormone (AMH) plays a role in neuroendocrine control of reproduction and in gonadotropin action (Barbotin et al., 2019). Anti-Müllerian hormone receptors were found in hypothalamic GnRH neurons and in gonadotrope-derived cell lines (Wang et al., 2009; Garrel et al., 2016). In vivo and in vitro experiments demonstrated that AMH acts on GnRH neurons thereby increasing LH pulsatility and secretion (Cimino et al., 2016) and that it interacts with both hypothalamic and pituitary cells to facilitate gonadotropin secretion (Silva and Giacobini, 2020). In addition, AMH inhibits follicle growth by decreasing the sensitivity of ovarian follicles to FSH (Durlinger et al., 2001) and exogenous AMH has been reported to decrease aromatase activity and the number of luteinizing hormone/choriogonadotropin receptors (LHCGRs) on granulosa cells in vitro (Grossman et al., 2008; Chang et al., 2013).

**Synergic action of LH and FSH in follicles**

The action of both LH and FSH is required for follicular growth. In the mid-follicular phase, LH-dependent and FSH-dependent synergistic action in granulosa cells ensures adequate steroidogenesis to stimulate follicle growth (Filicori et al., 2003; Duggavathi and Murphy, 2009; Casarini et al., 2018a). In vitro studies confirmed that the synergistic action of LH and FSH regulates the proliferative and anti-apoptotic effects that occur across the menstrual cycle i.e. folliculogenesis, granulosa cell growth, ovulation triggering, and maintenance of the corpus luteum (Casarini et al., 2011, 2016, 2018b). Furthermore, the combination of FSH and LH was found to activate progesterone and E2 production in human granulosa lutein cells (Casarini et al., 2016). The synergy between LH and FSH is even more striking at receptor level. FSH receptors (FSHRs) are expressed on the granulosa cells of the developing ovarian follicle, while LHCGRs are found on three distinct cell types: the theca cells of the early antral follicle, the mural granulosa cells of the periovulatory Graafian follicle induced by FSH/FSHR, and the luteal cells of the corpus luteum. Like many G protein-coupled receptors (GPCRs), FSHR and LHCGR can form receptor homodimers/oligomers, and can also form heteromers (Feng et al., 2013; Hanyaloglu et al., 2017) (Fig. 2). This complexity may explain why in mid-late follicular phase, when both LHCGRs and FSHRs are expressed on granulosa cells, FSH is sufficient for follicular growth even in the presence of very low LH levels, while LH levels rise, LHCGR/FSHR heteromers may then promote the LH-mediated pathways required for ovulation and luteinization (Feng et al., 2013; Jonas et al., 2018). Also the precise intracellular localization of both LHCGR and FSHR is critical for gonadotropin signalling (Jean-Alphonse et al., 2014; Sposini et al., 2017, 2020). The downstream functions of receptor signalling from intracellular compartments have yet to be determined, but LHCGR may be needed for oocyte maturation (Lyga et al., 2016) and androgen production, as shown in mouse and bovine ovarian models (Comim et al., 2013). At the receptor level, diverse FSH glycoforms may activate distinct FSH signalling with greater or lesser efficacy, a phenomenon known as ‘biased agonism’ (Landomiel et al., 2019; Zariñán et al., 2020), and this may have a profound effect on the cell proliferation rate and/or steroidogenesis.
The effect of different LH and FSH glycosylation variants and female age on LH and FSH action

The glycosylation of LH and FSH varies throughout the menstrual cycle and across reproductive life, thus impacting the half-life and activity of gonadotropins (Ulloa-Aguirre et al., 1988; Wide et al., 2007; Wide and Eriksson, 2018). Glycosylation variants have differential activity in vivo (Wide and Eriksson, 2013). While the proportion of the acidic FSH isoforms is higher during the early to mid-follicular phase than in the pre-ovulatory phase, the more basic FSH isoforms are secreted before ovulation (Anobile et al., 1998). Moreover, the half-lives of the LH and FSH isoforms are shorter, whereas their activity is greater in young post-pubertal women than in post-menopausal women (Wide et al., 2007; Choi and Smitz, 2014).

The decreased fertility observed with ageing (women > 35 years of age) is associated with an increase of fully glycosylated FSH variants that have a lower affinity for the FSHR versus the most common isoforms found in younger women (Anobile et al., 1998; Ulloa-Aguirre et al., 2001; Bousfield et al., 2018). Also LH isoforms change to less bioactive isoforms with ageing, i.e. more sialylated and less sulfonated LH isoforms (Wide et al., 2007). The reduced action of circulating gonadotropins caused by ageing results in reduced steroidogenesis and decreased ovarian function (Zumoff et al., 1995; Vihko, 1996; Davison et al., 2005). In the perimenopausal transition period, there is a tendency towards increasing levels of serum gonadotropins and decreasing levels of E2, and a statistically significant negative correlation between LHCGRs and serum LH levels (Vihko, 1996). Moreover, various studies reported that decreased LH activity in ageing women impairs androgen production (Zumoff et al., 1995; Davison et al., 2005). In fact, circulating levels of androgens have been reported to be much lower in advanced maternal age (AMA) women than in younger women (Zumoff et al., 1995; Mushayandebvu et al., 1996; Davison et al., 2005).

The effect of genetic variants of LH, FSH and their receptors on LH and FSH action

LH and FSH deficiency can also be associated with genetic variants in either the β subunit or in LH and FSH receptors (Achermann et al., 2002;
Mutations in FSHB have been reported in women with delayed puberty, absent breast development, and primary amenorrhea (Matthews et al., 1993; Layman et al., 1997). The FSHR gene variant at position –29 was associated with increased serum FSH levels in subjects with primary amenorrhea (Achrekar et al., 2010). LHB gene mutations seem to be less frequent, but in males, these mutations were related to delayed puberty, low testosterone, and arrested spermatogenesis in the presence of elevated serum LH (Weiss et al., 1992). Heterozygous LHB mutation in women may be associated with infertility (Achermann et al., 2002). In addition, homozygous LHCGR mutations are associated with oligomenorrhea or amenorrhea despite normal pubertal development (Latronico et al., 1998). Also, polymorphisms of FSH, LH, and their receptors have been related to reduced fertility in terms of reduced activity of endogenous gonadotropins or resistance to OS that result in a lower than expected oocyte yield (Simoni et al., 2002; Desai et al., 2013; Conforti et al., 2019d). Furthermore, polymorphisms of the FSHB promoter and FSHR were associated with lower FSH levels, a longer menstrual cycles, and age at menopause (Ruth et al., 2016; Rull et al., 2018). The specific implications of polymorphisms in assisted reproduction are discussed below.

**Clinical presentation of LH and FSH deficiency**

Deficiency of LH and FSH is caused by reduced gonadotropin production or action due to internal and external factors (Fig. 3). These conditions are generally characterised by low E2 and low-normal gonadotropins (Yasmin et al., 2013; Gordon et al., 2017). Congenital abnormalities are well described rare conditions that usually present with deficient GnRH secretion occurring in isolation or in association with anosmia (Kallmann syndrome) (Kallmann et al., 1944; Boehm et al., 2015). Among acquired conditions, intensive exercise and eating disorders are widely recognised as lifestyle factors that could suppress the HPG axis (Boyar et al., 1974; Shangold, 1985). Furthermore, poorly controlled diabetes and thyroid disorders could significantly affect gonadotropin secretion and action. To restore reproductive function, stress habits should be corrected and the underlying endocrine disorder be treated (Strotmeyer et al., 2003; Gordon, 2010). Other acquired conditions of reduced LH and FSH action could be linked to pituitary tumours (e.g. prolactinomas) or pituitary infarct (e.g. Sheehan’s syndrome) that are usually characterised by specific symptoms due to pituitary dysfunction or compression of tissues surrounding the pituitary or that can severely affect pituitary function beyond reproductive function (e.g. panhypopituitarism) (Li and Ng, 2012). All these conditions are in line with the ICMART definition of hypogonadotropic hypogonadism being associated with reduced gametogenesis and steroidogenesis due to reduced gonadotropin production or action. In MAR, a combination of factors such as AMA and genetic variants of gonadotropins, or their receptors that impair gonadotropin action, may further exacerbate the transient reduced LH and FSH production caused by GnRH analogues, and result in a low or sub-optimal response to OS (Alviggi et al., 2016a; Conforti et al., 2019a, 2019c).
LH and FSH deficiency in medically assisted reproduction

LH and FSH deficiency induced by GnRH analogue protocols

GnRH agonists and antagonists cause transient LH and FSH deficiency and are used during OS to prevent premature ovulation, thus enabling retrieval of more oocytes (Zegers-Hochschild et al., 2017). GnRH agonists and antagonists have different modes of action. GnRH agonists, after an initial increase in LH and FSH secretion (flare up), induce downregulation of the GnRH receptor (Lambalk et al., 2017). Conversely, GnRH antagonists competitively block the GnRH receptor thereby preserving pituitary gland responsiveness, so that gonadotropin levels are restored within a few hours of discontinuing suppression (Duijkers et al., 1998). Usually, the residual circulating levels of LH are sufficient to support steroidogenesis in theca cells, and recombinant human FSH (r-hFSH) is sufficient for OS. However, LH levels much lower than baseline can negatively affect MAR outcomes in some women (Westergaard et al., 2000; Humaidan et al., 2002). Thus, it is not clear to which extent serum LH levels are predictive of reproductive outcome in GnRH agonist cycles. However, it should be noted that different LH threshold values were used in different studies to define low LH groups (i.e. <1.5–0.5 IU/l LH) (Westergaard et al., 2000; Balasch et al., 2001; Humaidan et al., 2002).

Profound LH suppression has also been reported in some women after the administration of GnRH antagonists. Huime et al. (2005) found that if the change in serum LH during GnRH antagonist administration was >-2.2 IU/l below baseline values, the chance of achieving a clinical pregnancy under standard OS was almost nil. Kol (2014) reported that, after treatment with a GnRH antagonist, LH was over suppressed in 26% of women and these patients had a significantly lower increase in E2 during the first 24 h after antagonist administration compared to women who were not over suppressed. The effect was reversed in these patients after the addition of recombinant human LH (r-hLH). It remains unclear if this strong suppression of LH levels in response to GnRH antagonists is observed only in some subgroups of patients. It is conceivable that it may be associated with the individual pharmacodynamic response to the GnRH antagonist. However, it has been suggested that the severity of the LH deficiency caused by GnRH antagonist treatment is not linked to absolute LH serum levels but
rather to the magnitude of suppression over time versus the baseline (Kol and Homburg, 2008).

Several studies have shown that r-hFSH and r-hLH co-treatment can improve OS in women with transient LH and FSH deficiency after GnRH agonist or antagonist treatment (Garcia-Velasco et al., 2007; Pezzuto et al., 2010), whereas two systematic reviews did not observe such an effect in the general population (Griesinger and Shapiro, 2011; Alviggi et al., 2018a). To evaluate the benefits of r-hFSH:r-hLH treatment, studies should include subgroups of patients who are more prone to develop LH and FSH deficiency after GnRH analogues, such as women of AMA and hypo-responders (Alviggi et al., 2018a, 2018b).

Reduced LH and FSH action in AMA women undergoing MAR

The impaired functioning of the LH and FSH systems in AMA women, reviewed above, could be exacerbated by the transient gonadotropin deficiency induced by GnRH analogue regimens during OS. Co-treatment with r-hFSH:r-hLH has been proposed in AMA women undergoing MAR (Humaidan et al., 2004; Alviggi et al., 2006). A meta-analysis of studies in women between the ages of 35 and 40 years found that r-hFSH:r-hLH co-treatment resulted in higher clinical pregnancy rates than r-hFSH monotherapy (Hill et al., 2012). Yonis et al. (2017) demonstrated that r-hLH addition could compensate for the LH deficiency observed in women above 35 years, and three randomised controlled trials, which were included in the Hill meta-analysis (Hill et al., 2012), found that co-treatment with r-hLH and r-hFSH in women between the ages of 35 and 39 years improved both live birth and implantation rates (Matorras et al., 2009; Bosch et al., 2011). This effect was not found in studies of women over the age of 40 years (Barrenetxea et al., 2008; König et al., 2013; Vuong et al., 2015). The latter finding is not surprising as there is a dramatic reduction in the proportion of normal euploid embryos in women over the age of 40 years (Ata et al., 2012), and currently there are no data to suggest that this effect can be compensated by r-hLH.

The benefit of r-hFSH:r-hLH treatment for AMA women may also be related to the effect of LH on oocyte maturation and embryo implantation. In fact, LH exerts an anti-apoptotic effect on cumulus cells and promotes the paracrine signalling involved in cell expansion and oocyte maturation during folliculogenesis (Ruvolo et al., 2007; Huang et al., 2015). In addition, LH modulates various signalling molecules involved in endometrial implantation namely, leukaemia inhibiting factor, colony-stimulating factor-1, interleukin-1, integrins, glycoednin and mucin 1, and may improve endometrial receptivity (Herrell et al., 2003; Tesarik et al., 2003).

Hypo-response to ovarian stimulation due to reduced LH and FSH action

LH and FSH action may be reduced by receptor and post-receptor defects that cause a reduced response to OS. In clinical trials, about 10–15% of normo-ovulatory and normo-gonadotropic women undergoing MAR had a hypo-response to OS with exogenous gonadotropins (Conforti et al., 2019a).

Ovarian hypo-response can be defined as an unexpected slow response or stagnated follicle growth during OS with standard-dose FSH monotherapy, or that may require a higher than expected dose of gonadotropins depending on age, body mass index and ovarian reserve (Alviggi et al., 2018b). A meta-analysis on hypo-response found that OS with r-hFSH:r-hLH resulted in significantly higher clinical pregnancy and implantation rates versus r-hFSH alone (Conforti et al., 2019b). Recently, two indices based on individual ovarian reserve have been proposed to measure the ovarian response to OS: the follicle output rate (FORT) (Genro et al., 2011) and the follicle-to-oocyte index (FOI) (Alviggi et al., 2018b). FORT measures the ratio of the number of pre-ovulatory follicles on the day of hCG trigger × 100 over the number of small antral follicles at baseline prior to OS, while FOI is the ratio between the number of oocytes collected at ovum pick up and the number of antral follicles at the beginning of OS. These two indices are a direct measure of the individual response to OS and can help to identify a hypo-response to OS better than oocyte number alone.

The pathophysiological mechanisms of hypo-response are not yet fully understood. In some cases, a hypo-response may be associated with LH and FSH single nucleotide polymorphisms (SNPs) and their receptors (Perez Mayorga et al., 2000; Alviggi et al., 2013; La Marca et al., 2013), but the exact prevalence of these SNPs in MAR is unknown because they are not routinely tested.

Reduced LH and FSH action in ovarian stimulation due to genetic variants

Some SNPs related to LH, FSH, and their receptors that reduce the activity of endogenous gonadotropins or induce ovarian resistance to OS due to receptor and post-receptor defects have been associated with reduced fertility (Simoni et al., 2002; Desai et al., 2013; Conforti et al., 2019d). A polymorphism of the FSH molecule that affects the FSH beta chain promoter (c.-221 G>T) seems to affect gonadotropin function (Grigorova et al., 2008; Schüring et al., 2013). Indeed, in a study of Finnish women of reproductive age, the T allele carriers were characterised by increased baseline serum LH and FSH levels, and by idiopathic infertility (Rull et al., 2018). In another study of 63,350 women, the T allele was associated with a longer menstrual cycle, later age at menopause and a reduced incidence of endometriosis (Ruth et al., 2016).

Also FSHR SNPs may be associated with a hypo-response to OS (Conforti et al., 2019d). Some variants of FSHR 680 c.2039G>A (rs6166) are related to higher FSH levels and to higher FSH consumption (Overbeek et al., 2009; Laisk-Podar et al., 2015; Alviggi et al., 2018c). FSHR -29 G>A (rs1394205) allele A carriers were found to have fewer FSHRs than allele G carriers, which translated in a higher FSH consumption during OS and a lower ovarian sensitivity in A carriers (Casarini et al., 2014; Riccetti et al., 2017). Also the FSHR c. G919A (rs6165) variant may affect ovarian response but not ovarian reserve (Achrekar et al., 2009; Trevisan et al., 2014; Alviggi et al., 2018c). Interestingly, different combinations of genetic variants of the FSH beta chain and of FSHR affect menstrual Day 3 serum FSH levels in women of reproductive age (La Marca et al., 2013).

Variants of the LH beta chain and of LHCGRs that affect OS have also been identified. A common variant of the LH beta chain (rs1800447) affects the LH system during OS (Haavisto et al., 1995; Alviggi et al., 2009a, 2013). Clinically, carriers of this LH variant are characterised by a less active form of LH that does not adequately support FSH activity during follicle stimulation, and consequently...
results in a reduced response to OS with FSH (Alviggi et al., 2009a, 2013). The LHCGR c.872A>G (rs12470652) polymorphism could affect ovarian response when associated with other polymorphisms. Indeed, the ratio between the cumulative FSH dose and the total number of oocytes retrieved was higher in carriers of allele C of FSHR -29 rs1394205, FSHR rs6166, and LHCGR 291 rs12470652 than in women who did not have allele C in at least one of these SNPs (Alviggi et al., 2016b). In addition, LHCGR S312N (c2293275) carriers required a higher FSH dosage during OS versus asparagine carriers (Lindgren et al., 2016). Thus, polymorphisms of the LH beta chain and of LHCGRs could reduce ovarian sensitivity to FSH, which suggests that the function of both gonadotropins is crucial during OS. In addition, the presence of serine instead of asparagine in Position 312 might lead to reduced sensitivity to LH action and may explain why carriers of this polymorphism required more r-hLH during OS than non-carriers (Ramaraju et al., 2018). Moreover, in the same study, the pregnancy rate was significantly higher in serine carriers who received r-hFSH: r-hLH than in those receiving r-hFSH alone (P=0.04) (Ramaraju et al., 2018).

**Understanding LH and FSH deficiency in MAR: where do we stand? Limitations and implications for future research**

LH and FSH deficiency is characterised by reduced LH and FSH production or action in the presence of normal-lower LH and FSH and low E2 levels. In specific subgroups of women (AMA women and women with a hypo-response to OS), LH and FSH deficiency may be the underlying cause of an unfavourable prognosis. Indeed, OS with r-hFSH:r-hLH has been reported to improve reproductive outcomes in these subgroups (Alviggi et al., 2018a). In addition, preliminary findings suggest that serine carriers of the LHCGR variant (rs 2293275) might require higher amounts of r-hLH during OS together with r-hFSH than do asparagine homozygous carriers (Ramaraju et al., 2018). Should these data be confirmed in larger studies, they will facilitate the identification of subpopulations of women with potential LH and FSH deficiency and consequently a poor MAR prognosis. Recently, the POSEIDON (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) group proposed a classification of low prognosis based on a confirmed or expected inappropriate ovarian response to gonadotropin stimulation (Alviggi et al., 2016a; Humaidan et al., 2016). The POSEIDON concept contributes to identifying more homogeneous populations for clinical studies. Indeed, a large retrospective study of 18,455 cycles found that, while the cumulative live birth rate was similar in younger patients with normal ovarian parameters and a poor prognosis (POSEIDON Groups 1 and 3, respectively), it was significantly lower in women of advanced age with a normal ovarian reserve (POSEIDON Group 2 vs. Group 1) (Shi et al., 2019). Interestingly, according to systematic reviews, pregnancy rate and implantation rate were higher in hypo-responders treated with r-FSH and r-hLH versus those treated with r-hFSH alone (Alviggi et al., 2018a; Conforti et al., 2019b). Nevertheless, to evaluate the effect of gonadotropins in women with potential LH and FSH deficiency, studies should include information on endocrinological and clinical outcomes. Relevant endocrine endpoints, including serum testosterone, serum E2 values and the E2/oocyte ratio could elucidate the stimulatory effect exerted by LH during OS on steroidogenesis in both theca and granulosa cells, and may lead to biomarkers for the diagnosis of LH and FSH deficiency before and during OS. Moreover, clinical end points such as FORT and FOI can directly measure the downstream clinical effect of gonadotropins in relation to the baseline antral follicle count. Ultimately, individualised treatment aimed at optimising FORT and FOI will reveal the highest number of oocytes attainable for each cycle and each patient. This in turn could increase the probability of live birth which is positively correlated with the number of good quality embryos (Vermey et al., 2019). Lastly, given that the probability of live birth is also related to endometrial receptivity, it is important to evaluate if and how different gonadotropin regimens affect endometrial receptivity, how the luteal phase can be effectively supported in women with potential LH and FSH deficiency (Revel, 2012), and when a freeze all strategy with subsequent frozen embryo transfer cycles is superior to embryo transfer in a fresh cycle with respect to efficacy and safety.

**Conclusions**

Reduced gonadotropin production or action may cause clinically significant LH and FSH deficiency associated with reduced gametogenesis and steroidogenesis. This may explain why some women treated with MAR have an ‘unexpected’ hypo-response to standard OS with r-hFSH alone, notwithstanding their normal gonadotropin levels and normal ovarian reserve, and may contribute to a reduced ovarian response in women of AMA. It may also pave the way to precision medicine solutions for fertility patients (Mol et al., 2018), and thus improve reproductive outcomes, particularly in AMA and hypo-responder patients who may benefit from OS with r-hFSH and r-hLH.

**Data availability**

No new data were generated or analysed in support of this research.

**Acknowledgements**

The authors thank Daniela Finizio and Jean Ann Gilder, Scientific Communication and Event Planet, Naples, Italy, for writing support.

**Authors’ roles**

All authors equally contributed to the conception of the work, co-wrote the initial draft, critically reviewed the content and approved the final version of the work.

**Funding**

Merck KGaA, Darmstadt, Germany funded the preparation of this article, including independent medical writing assistance.
Conflict of interest

D.C., T.D.H., and M.L. are employees of Merck KGaA, Darmstadt, Germany; C.A., A.C., and P.C. report personal fees from Merck KGaA, Darmstadt, Germany during the submitted work; E.B. received consulting fees from Abbott, Ferrin, Gedeon Richter, Merck KGaA, Darmstadt, Germany, and Roche, speakers bureau and honoraria fees from Ferrin, Gedeon Richter, Merck KGaA, Darmstadt, Germany, and Roche and Research Cooperation with Gedeon Richter; A.C.H. reports personal fees from Imperial Consultants during the conduct of the study; P.H. received personal fees from Merck KGaA, Darmstadt, Germany during the conduct of the study; grants and personal fees from IBSA, Gedeon Richter, Merck KGaA, Darmstadt, Germany, and MSD outside the submitted work; S.K. received personal fees and grants from Merck KGaA, Darmstadt, Germany during and outside the submitted work; M.S. received grants and personal fees from Ferrin, IBSA and Merck KGaA, Darmstadt, Germany during and outside the conduct of the submitted work; N.R.F. has nothing to disclose; V.R. reports personal fees from Merck KGaA, Darmstadt, Germany and Novartis, and grants from Ipsen outside the submitted work.

References

Achermann JC, Ozisik G, Meeks JJ, Jameson JL. Genetic causes of human reproductive disease. J Clin Endocrinol Metab 2002;87:2447–2454.

Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV, Mahale SD. Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women. Fertil Steril 2009;91:432–439.

Achrekar SK, Modi DN, Meherji PK, Patel ZM, Mahale SD. Follicle stimulating hormone receptor gene variants in women with primary and secondary amenorrhea. J Assist Reprod Genet 2010;27:317–326.

Alviggi C, Andersen CY, Buehler K, Conforti A, De Placidog C, Esteves SC, Fischer R, Galliano D, Polyzos NP, Sunkara SK, POSEIDON Group (Patient-Oriented Strategies Encompassing Individualized Oocyte Number) et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril 2016a;105:1452–1453.

Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I, Coppola M, Ranieri A, D’Uva M, De Placidog G. Suboptimal response to GnRHα long protocol is associated with a common LH polymorphism. Reprod Biomed Online 2009a;18:9–14.

Alviggi C, Conforti A, Cariati F, Alfano S, Strina I, Huhtaniemi I, Santi D, De PG, Humaidan P. Impact of polymorphisms of gonadotropins and their receptors on controlled ovarian stimulation: a prospective observational study. Abstr 32nd Annu Meet ESHRE Hels Finl 3 July – 6 July 2016b.

Alviggi C, Conforti A, Esteves SC, Andersen CY, Bosch E, Bühler K, Ferraretti AP, De Placidog G, Mollo A, Fischer R, et al. Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertil Steril 2018a;109:644–664.

Alviggi C, Conforti A, Esteves SC, Vallone R, Venturella R, Staiano S, Castaldo E, Andersen CY, De Placidog G. Understanding ovarian hypo-response to exogenous gonadotropin in ovarian stimulation and its new proposed Marker-The Follicle-To-Oocyte (FOI) Index. Front Endocrinol (Lausanne) 2018b;9:589.

Alviggi C, Conforti A, Santi D, Esteves SC, Andersen CY, Humaidan P, Chiodini P, De Placidog C, Simoni M. Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis. Hum Reprod Update 2018c;24:599–614.

Alviggi C, Humaidan P, Howles CM, Tredway D, Hillier SG. Biological versus chronological ovarian age: implications for assisted reproductive technology. Reprod Biol Endocrinol 2009b;7:101.

Alviggi C, Mollo A, Clarizia R, De Placidog G. Exploiting LH in ovarian stimulation. Reprod Biomed Online 2006;12:221–233.

Alviggi C, Pettersson K, Longobardi S, Andersen CY, Conforti A, De Rosa P, Clarizia R, Strina I, Mollo A, De Placidog G. et al. A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology. Reprod Biol Endocrinol 2013;11:51.

Anobile Cj. Talbot JA, McCann Sj, Padmanabhan V, Robertson WR. Glycoform composition of serum gonadotrophins through the normal menstrual cycle and in the post-menopausal state. Mol Hum Reprod 1998;4:631–639.

Ata B, Kaplan B, Danzer H, Glassner M, Opsahl M, Tan SL, Munné S. Array CGH analysis shows that aneuploidy is not related to the number of embryos generated. Reprod Biomed Online 2012;24:614–620.

Balasch J, Vidal E, Peñarrubia J, Casamitjana R, Carmona F, Creus M, Fábregues F, Vanrell JA. Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. Hum Reprod Oxf Engl 2001;16:1636–1643.

Barbotin A-L, Peigne M, Malone SA, Giacobini P. Emerging roles of anti-Müllerian hormone in hypothalamic-pituitary function. Neuroendocrinology 2019;109:218–229.

Barrenetxea G, Agirregoikoaa JA, Jiménez MR, de Larruzeaa AL, Ganzabal T, Carbonero K. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil Steril 2008;89:546–553.

Benmachiche A, Benbouhedja S, Zoghmar A, Humaidan P, Low LH level on the day of GnRH agonist trigger is associated with reduced ongoing pregnancy and live birth rates and increased early miscarriage rates following IVF/ICSI treatment and fresh embryo transfer. Front Endocrinol 2019;10:639.

Berga S, Naftolin F. Neuroendocrine control of ovulation. Gynecol Endocrinol Off Endocrinol 2012;28 Suppl 1:9–13.

Bianco SDC, Kaiser UB. The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. Nat Rev Endocrinol 2009;5:569–576.

Boehm U, Bouloux P-M, Dattani MT, N de R, Dodé C, Dunkel L, Dwyer AA, Giacobini P, Hardelin J-P, Juul A. et al. Expert consensus document: European Consensus Statement on congenital...
Reduced FSH and LH action in assisted reproduction

Boyar RM, Katz J, Finkelstein JW, Kapen S, Weiner H, Weitzman Bousfield GR, May JV, Davis JS, Dias JA, Kumar TR. In vivo and Casarini L, Santi D, Brigante G, Simoni M. Two hormones for one Reduced FSH and LH action in assisted reproduction Casarini L, Santi D, Simoni M, Potì F. “Spare” luteinizing hormone treatment. Comim FV, Hardy K, Franks S. Adiponectin and its receptors in the Chang H-M, Klausen C, Leung PCK. Antimu¨llerian hormone inhibits follicle-stimulating hormone-induced adenylyl cyclase activation, aromatase expression, and estradiol production in human granulosa-lutein cells. Fertil Steril 2013;100:585–592.e1. Chen C-D, Chiang Y-T, Yang P-K, Chen M-J, Chang C-H, Yang Y-S, Chen S-U. Frequency of low serum LH is associated with increased early pregnancy loss in IVF/ICSI cycles. Reprod Biomed Online 2016;33:449–457. Choi J, Smitz J. Luteinizing hormone and human chorionic gonadotropin: origins of difference. Mol Cell Endocrinol 2014;383:203–213. Cimino I, Casoni F, Liu X, Messina A, Parkash J, Jamin SP, Cimadomo D, Barocini M, Dewailly D. et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun 2016;7:10055. Comim FV, Hardy K, Franks S. Adiponectin and its receptors in the ovary: further evidence for a link between obesity and hyperandroge- ninism in polycystic ovary syndrome. PLoS One 2013;8:e80416. Conforti A, Esteves SC, Cinadomo D, Vaiarelli A, Di Rella F, Ubaldi FM, Zullo F, De Placido G, Alivaggi C, Management of women with an unexpected low ovarian response to gonadotropin. Front Endocrinol 2019a;10:387. Conforti A, Esteves SC, Di Rella F, Strina I, De Rosa P, Furlonge A, Zullo F, De Placido G, Alivaggi C. The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systemic review and meta-analysis. Reprod Biol Endocrinol 2019b;17:18. Conforti A, Esteves SC, Picarelli S, Iorio G, Rania E, Zullo F, De Placido G, Alivaggi C. Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: the POSEIDON concept. Panminerva Med 2019c;61:24–29. Conforti A, Vaiarelli A, Cinadomo D, Bagnulo F, Peluso S, Carbone L, Di Rella F, De Placido G, Ubaldi FM, Huhtaniemi I. et al. Pharmacogenetics of FSH action in the female. Front Endocrinol (Lausanne) 2019d;10:398. Conn PM, Crowley WF. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994;45:391–405. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847–3853. Desai SS, Roy BS, Mahale SD. Mutations and polymorphisms in FSH receptor: functional implications in human reproduction. Reproduction 2013;146:R235–R248. Duggavat R, Murphy BD. Development. Ovulation signals. Science 2009;324:890–891. Duijkers IJ, Klipping C, Willemsen WN, Krone D, Schneider E, Niebgh C, Hermann R. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Hum Reprod Oxf Reprod 1998;13:2392–2398. Durlinger AL, Gruijters MJ, Kramer P, Kares B, Kumar TR, Matzuk MM, Rose UM, Jonk FH, de Uilenbroek JT, Grootegoed JA. et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001;142:4891–4899. Feng X, Zhang M, Guan R, Segaloff DL. Heterodimerization between the lutropin and follitropin receptors is associated with an attenuation of hormone-dependent signaling. Endocrinology 2013;154:3925–3930. Filiponi M, Cognigni GE, Pocognoli P, Ciampaglia W, Bernardi S. Current concepts and novel applications of LH activity in ovarian stimulation. Trends Endocrinol Metab TEM 2003;14:267–273. Garcia-Velasco JA, Coelingh Bennink HJT, Epifanio R, Escudero E, Pellicer A, Simón C. High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist. Reprod Biomed Online 2007;15:280–287. Garrel G, Racine C, L’Hôte D, Denoyelle C, Guigon CJ, di Clemente N, Cohen-Tannoudji J. Anti-Müllerian hormone: a new actor of sexual dimorphism in pituitary gonadotrope activity before puberty. Sci Rep 2016;6:23790. Genro VK, Grynberg M, Scheffer JB, Roux I, Frydman R, Fanchin R. Serum anti-Müllerian hormone levels are negatively related to prognosis patients in assisted reproductive technology. J Clin Endocrinol Metab 2019;102:1413–1439.
Griesinger G, Shapiro DB. Luteinizing hormone add-back: is it needed in controlled ovarian stimulation, and if so, when? J Reprod Med 2011;56:279–300.

Grigorova M, Punab M, Ausmees K, Laan M. FSHB promoter polymorphism within evolutionary conserved element is associated with serum FSH level in men. Hum Reprod 2008;23:2160–2166.

Grossman MP, Nakajima ST, Fallat ME, Siow Y. Müllerian-inhibiting

Bosch Hanyaloglu A, Fanelli F, Jonas K. Class A GPCR: Di/oligomerization in human gonadotropin-receptor genes. In Receptors. Totowa, NJ: Humana Press Springer International2017, 207–231. [Internet]. Available from: 10.1007/978-3-319-60174-8_8.

Herrler A, von RU, Beier HM. Embryo-maternal signalling: how the embryo starts talking to its mother to accomplish implantation. Reprod Biomed Online 2003;6:244–256.

Huang Y, Zhao Y, Yu Y, Li R, Lin S, Zhang C, Liu P, Qiao J. Altered amphiregulin expression induced by diverse luteinizing hormone receptor reactivity in granulosa cells affects IVF outcomes. Reprod Biomed Online 2015;30:593–601.

Huhtaniemi IT, Themmen APN. Mutations in human gonadotropin-receptor genes. Endocrine 2005;26:207–217.

Huang Y, Zhao Y, Yu Y, Li R, Lin S, Zhang C, Liu P, Qiao J. Altered amphiregulin expression induced by diverse luteinizing hormone receptor reactivity in granulosa cells affects IVF outcomes. Reprod Biomed Online 2015;30:593–601.

Humaidan P, Hanyaloglu A, Fanelli F, Jonas K. Class A GPCR: Di/oligomerization in human gonadotropin-receptor genes. In Receptors. Totowa, NJ: Humana Press Springer International2017, 207–231. [Internet]. Available from: 10.1007/978-3-319-60174-8_8.

Humaidan P, Bungum M, Bungum L, Cilio C, Leijonhufvud I. Occurrence and biological properties of a common genetic variant of luteinizing hormone. J Clin Endocrinol Metab 1995;80:1257–1263.

Humaidan P, Hanyaloglu A, Fanelli F, Jonas K. Class A GPCR: Di/oligomerization in human gonadotropin-receptor genes. In Receptors. Totowa, NJ: Humana Press Springer International2017, 207–231. [Internet]. Available from: 10.1007/978-3-319-60174-8_8.

Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON knowledgebase: a tool to assess polymorphisms in the LHCGR and FSHR genes needed in controlled ovarian stimulation, and if so, when? J Reprod Med 2011;56:279–300.

Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online 2004;8:635–643.

Jean-Alphonse F, Bowersox S, Chen S, Beard G, Puthenveedu MA, Hanyaloglu AC. Spatially restricted G protein-coupled receptor activity via divergent endocytic compartments. J Biol Chem 2014;289:3960–3977.

Jonas KC, Chen S, Virta M, Mora J, Franks S, Huhtaniemi I, Hanyaloglu AC. Temporal reprogramming of calcium signalling via crosstalk of gonadotrophin receptors that associate as functionally asymmetric heteromers. Sci Rep 2018;8:2239.

Kaiser UB, Jakubowiak A, Steinberger A, Chin WW. Differential effects of gonadotropin-releasing hormone (GnRH) pulse frequency on gonadotropin subunit and GnRH receptor messenger ribonucleic acid levels in vitro. Endocrinology 1997;138:1224–1231.

Kallmann FJ, Schoenfeld WA, Barrera SE. The genetic aspects of primary eunuchoidism. Am J Ment Def 1944;48:203–236.

Kol S. Individualized treatment from theory to practice: the private case of adding LH during GnRH antagonist-based stimulation protocol. Clin Med Insights Reprod Health 2014;8:59–64.

Kol S, Homburg R. Change, change, change: hormonal actions depend on changes in blood levels. Hum Reprod 2008;23:1004–1006.

König TE, van der Houwen Lee, Overbeek A, Hendriks ML, Beutler-Beemsterboer SN, Kuchener Becker WKH, Renckens CNM, Bernardus RE, Schats R, Homburg R, et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod 2013;28:2804–2812.

Kol S, Homburg R. Change, change, change: hormonal actions depend on changes in blood levels. Hum Reprod 2008;23:1004–1006.

Kol S, Homburg R. Change, change, change: hormonal actions depend on changes in blood levels. Hum Reprod 2008;23:1004–1006.

Kol S, Homburg R. Change, change, change: hormonal actions depend on changes in blood levels. Hum Reprod 2008;23:1004–1006.
Tesarik J, Hazout A, Mendoza C. Luteinizing hormone affects uterine receptivity independently of ovarian function. Reprod Biomed Online 2003;7:59–64.

Trevisan CM, Peluso C, Cordts EB, R de O, Christofolini DM, Barbosa CP, Bianco B. Ala307Thr and Asn680Ser polymorphisms of FSHR gene in human reproduction outcomes. Cell Physiol Biochem Int Biochem 2014;34:1527–1535.

Ulloa-Aguirre A, Espinoza R, Damian-Matsumura P, Chappel SC. Immunological and biological potencies of the different molecular species of gonadotrophins. Hum Reprod Oxf Reprod 1988;3:491–501.

Trevisan CM, Peluso C, Cordts EB, R de O, Christofolini DM, Barbosa CP, Bianco B. Ala307Thr and Asn680Ser polymorphisms of FSHR gene in human reproduction outcomes. Cell Physiol Biochem Int Biochem 2014;34:1527–1535.

Ulloa-Aguirre A, Espinoza R, Damian-Matsumura P, Chappel SC. Immunological and biological potencies of the different molecular species of gonadotrophins. Hum Reprod Oxf Reprod 1988;3:491–501.

Vermey BG, Chua SJ, Zafarmand MH, Wang R, Longobardi S, Cottell E, Beckers F, Mol BW, Venetis CA, D’Hooghe T. Is there an association between oocyte number and embryo quality? A systematic review and meta-analysis. Reprod Biomed Online 2019;39:751–763.

Vihko KK. Gonadotropins and ovarian gonadotropin receptors during the perimenopausal transition period. Maturitas 1996;23 Suppl: S19–S22.

Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Hum Reprod Oxf Reprod 2015;30:1188–1195.

Wang P-Y, Protheroe A, Clarkson AN, Imhoff F, Koishi K, McLennan IS. Müllerian inhibiting substance contributes to sex-linked biases in the brain and behavior. Proc Natl Acad Sci U S A 2009;106:7203–7208.

Weiss J, Axelrod L, Whitcomb RW, Harris PE, Crowley WF, Jameson JL. Hypogonadism caused by a single amino acid substitution in the beta subunit of luteinizing hormone. N Engl J Med 1992;326:179–183.

Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod Oxf Engl 2000;15:1003–1008.

Wide L, Eriksson K. Dynamic changes in glycosylation and glycan composition of serum FSH and LH during natural ovarian stimulation. Ups J Med Sci 2013;118:153–164.

Wide L, Eriksson K. Low-glycosylated forms of both FSH and LH play major roles in the natural ovarian stimulation. Ups J Med Sci 2018;123:100–108.

Wide L, Eriksson K, Sluss PM, Hall JE. Serum half-life of pituitary gonadotropins is decreased by sulfonation and increased by sialylation in women. J Clin Endocrinol Metab 2009;94:958–964.

Younis JS, Izhaki I, Ben-Ami M. The effect of rLH supplementation to the GnRH-antagonist protocol on endocrine dynamics in the advanced reproductive age. J Endocrinol Invest 2017;40:831–839.

Zariñán T, Butnev VY, Gutiérrez-Sagal R, Maravillas-Montero JL, Martínez-Luis I, Mejía-Dominguez NR, Juárez-Vega G, Bousfield GR, Ulloa-Aguirre A. In vitro impact of FSH glycosylation variants on FSH receptor-stimulated signal transduction and functional selectivity. J Endocr Soc [Internet] 2020;4:bvaa019.

Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, Rienzi L, Sunde A, Schmidt L, Cooke ID. et al. The international glossary on infertility and fertility care, 2017. Hum Reprod Oxf Reprod 2017;32:1786–1801.

Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995;80:1429–1430.